Compare Boston Scientific Corporation (BSX) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs JPMorgan Chase & Co — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while JPMorgan Chase & Co trades at $344.7 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 13.7× Boston Scientific Corporation's market cap, and JPMorgan Chase & Co pays a 1.75% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | JPM | |
|---|---|---|
Market Cap | $66.37B | $911.47B |
Sector | Health | Financials |
52-Week High | $108.14 | $342.89 |
52-Week Low | $42.63 | $282.84 |
Enterprise Value | $75.94B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
JPMorgan Chase (JPM) trades at $334.53, down 0.58% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $186.4B projected for 2026. The stock shows a P/E of 14.69 and ROE of 17.03%, supported by a 'Moderate Buy' analyst consensus and a $377.75 price target. News highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
Outlook remains positive with earnings momentum and institutional support, but risks include geopolitical tensions, cybersecurity threats from AI, and volatile cash flows. The stock offers value with upside potential, though investors should monitor economic headwinds and interest rate impacts on banking performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
